TABLE 3.
Medication Compliance (MPR) and Persistence (PDC) for First-Line Therapies for mRCC (N = 476)
| Medication | MPR | PDC | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicare | Commercial | Total | Medicare | Commercial | Total | |||||||
| n | MPR ≥ 80% | n | MPR ≥ 80% | n | MPR ≥ 80% | n | PDC ≥ 80% | n | PDC ≥ 80% | n | PDC ≥ 80% | |
| Injectable | ||||||||||||
| Bevacizumab | 8 | 62.5% | 5 | 60.0% | 13 | 61.5% | 12 | 75.0% | 5 | 60.0% | 17 | 70.6% |
| Temsirolimus | 64 | 67.2% | 11 | 81.8% | 75 | 69.3% | 71 | 76.1% | 11 | 90.9% | 86 | 78.0% |
| P = 0.58a | P = 0.51a | |||||||||||
| Oral | ||||||||||||
| Everolimus | 12 | 75.0% | 3 | 66.7% | 15 | 73.3% | 15 | 80.0% | 4 | 100.0% | 19 | 84.2% |
| Pazopanib | 31 | 77.4% | 6 | 83.3% | 37 | 78.4% | 44 | 88.6% | 6 | 83.3% | 50 | 88.0% |
| Sorafenib | 49 | 65.3% | 6 | 83.3% | 55 | 67.3% | 59 | 81.4% | 7 | 85.7% | 66 | 81.8% |
| Sunitinib | 147 | 81.0% | 48 | 79.2% | 195 | 80.5% | 186 | 91.9% | 48 | 87.5% | 234 | 91.0% |
| P = 0.21a | P = 0.19a | |||||||||||
| Total injectable | 88 | 68% | 99 | 77% | ||||||||
| Total oral | 302 | 77% | 369 | 89% | ||||||||
| P = 0.75a | P = 0.002a | |||||||||||
aP values were calculated by chi-square test (P < 0.05 was considered significant).
MPR = medication possession ratio; mRCC = metastatic renal cell carcinoma; PDC = proportion of days covered.